Engineered IgE-sensitized mast cells (IgE-MCs) could serve as an elegant and conceptually innovative platform for tumor-targeted oncolytic virus delivery, mediating tumor-specific targeting and synchronized immune activation within the tumor microenvironment (TME). In a recent study in Cell, Xu et al. demonstrate robust antitumor efficacy of IgE-MCs and shed further light on personalized immunotherapy and broadly adaptable delivery paradigms.
Mao et al. (Thu,) studied this question.